Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LVTX LAVA Therapeutics	$1.52 -1.3%	$1.40	$0.85 ▼ $2.09	$39.98M	0.5	159,720 shs	192,254 shs
QHC Quorum Health	$0.30	$0.37	$0.22 ▼ $2.49	$10.01M	2.29	266,388 shs	N/A
SNTI Senti Biosciences	$1.52 -0.7%	$2.07	$1.46 ▼ $16.94	$39.76M	2.07	145,397 shs	73,302 shs
SSY SunLink Health Systems	$1.12 +16.6%	$1.03	$0.62 ▼ $1.91	$7.85M	1.16	145,367 shs	243,934 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LVTX LAVA Therapeutics	0.00%	-0.65%	+8.57%	+21.60%	-14.12%
QHC Quorum Health	0.00%	0.00%	0.00%	0.00%	0.00%
SNTI Senti Biosciences	0.00%	-3.80%	-24.38%	-52.20%	-29.95%
SSY SunLink Health Systems	0.00%	+9.71%	-0.09%	+35.47%	+42.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LVTX LAVA Therapeutics	2.1975 of 5 stars	3.0	5.0	0.0	0.0	2.9	0.0	0.0
QHC Quorum Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	2.9251 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.0	0.6
SSY SunLink Health Systems	2.3837 of 5 stars	0.0	5.0	0.0	0.0	1.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LVTX LAVA Therapeutics	2.00	Hold	$2.69	76.64% Upside
QHC Quorum Health	0.00	N/A	N/A	N/A
SNTI Senti Biosciences	3.00	Buy	$8.50	459.21% Upside
SSY SunLink Health Systems	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QHC, SSY, LVTX, and SNTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LVTX LAVA Therapeutics	$4.99M	8.01	N/A	N/A	$0.76 per share	2.00
QHC Quorum Health	$1.88B	0.01	$0.66 per share	0.46	($2.38) per share	-0.13
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	$0.94 per share	N/A
SSY SunLink Health Systems	$31.09M	0.25	N/A	N/A	$2.27 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LVTX LAVA Therapeutics	-$25.11M	-$1.05	N/A	N/A	N/A	N/A	-106.29%	-38.24%	8/19/2025 (Estimated)
QHC Quorum Health	-$200.25M	N/A	N/A	∞	N/A	-8.65%	N/A	-4.00%	N/A
SNTI Senti Biosciences	-$52.79M	-$8.95	N/A	N/A	N/A	N/A	-223.98%	-76.02%	N/A
SSY SunLink Health Systems	-$1.53M	$0.24	4.66	∞	N/A	5.55%	-18.98%	-14.79%	N/A

Latest QHC, SSY, LVTX, and SNTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A
8/7/2025	Q2 2025	SNTI Senti Biosciences	-$0.58	-$0.56	+$0.02	-$0.56	$1.30 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
QHC Quorum Health	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A
SSY SunLink Health Systems	N/A	N/A	N/A	N/A	N/A

Latest QHC, SSY, LVTX, and SNTI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/21/2025	SSY SunLink Health Systems	special	$0.10			7/29/2025	7/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LVTX LAVA Therapeutics	N/A	10.78	6.73
QHC Quorum Health	N/A	1.21	1.10
SNTI Senti Biosciences	N/A	3.26	4.22
SSY SunLink Health Systems	N/A	3.91	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LVTX LAVA Therapeutics	N/A
QHC Quorum Health	58.36%
SNTI Senti Biosciences	25.73%
SSY SunLink Health Systems	23.67%

Insider Ownership

Company	Insider Ownership
LVTX LAVA Therapeutics	9.50%
QHC Quorum Health	6.10%
SNTI Senti Biosciences	3.12%
SSY SunLink Health Systems	27.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
QHC Quorum Health	11,600	32.92 million	N/A	Optionable
SNTI Senti Biosciences	4	26.16 million	25.34 million	Not Optionable
SSY SunLink Health Systems	1,376	7.04 million	5.08 million	Not Optionable

QHC, SSY, LVTX, and SNTI Headlines

Recent News About These Companies

Sunlink Health Systems Completes Merger with Regional Health

August 14 at 10:57 PM | msn.com

SunLink Health Systems (NYSE:SSY) Trading Down 7.6% - What's Next?

August 12, 2025 | americanbankingnews.com

Regional Health Properties, Inc. and SunLink Health Systems, Inc. ...

August 4, 2025 | gurufocus.com

Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger

August 4, 2025 | businesswire.com

Regional Health Properties, Inc. and SunLink Health Systems, Inc. ...

August 4, 2025 | gurufocus.com

SunLink Health Systems, Inc. Adjourns Special Meeting Until August 4, 2025 and Urges Stockholders of Record as of June 20, 2025 to Vote FOR the Proposed Merger With Regional Health Properties, Inc. by August 3, 2025 at 11:59 PM EDT

July 29, 2025 | businesswire.com

A Closer Look at SunLink’s (SSY) Special Dividend

July 26, 2025 | msn.com

Sunlink Health Systems Receives NYSE American Deficiency Notice

July 26, 2025 | theglobeandmail.com

SunLink Health Systems updates on planned special cash dividend

July 24, 2025 | msn.com

SunLink Health Systems, Inc. provides an Update on Proxy Voting for the Proposed Merger with Regional Health Properties, Inc. and Urges Stockholders of Record as of June 20, 2025 to Vote FOR the Proposed Merger by July 28, 2025 at 11:59 PM EDT

July 24, 2025 | businesswire.com

SunLink Health Systems, Inc. Provides Update on Special Cash Dividend Scheduled to Be Paid Prior to SunLink's Proposed Merger with Regional Health Properties, Inc.

July 24, 2025 | businesswire.com

SunLink Health Systems, Inc Declares Special Cash Dividend Prior to with the Proposed Merger with Regional Health Properties, Inc.

July 21, 2025 | businesswire.com

SunLink Health Systems Declares 10c Special Div

July 19, 2025 | marketwatch.com

SunLink Health Systems Announces That It Received a NYSE American LLC Notice Indicating That SunLink Has Fallen Below Certain NYSE American Continued Listing ... - Morningstar

July 8, 2025 | morningstar.comM

SunLink Health Systems Announces That It Received a NYSE American LLC Notice Indicating That SunLink Has Fallen Below Certain NYSE American Continued Listing Standards

July 7, 2025 | businesswire.com

Sunlink Health Systems Extends Merger Agreement Deadline

June 23, 2025 | tipranks.com

SunLink Health Systems, Inc. Announces Fiscal 2025 Third Quarter Results

May 13, 2025 | businesswire.com

REGIONAL HEALTH PROPERTIES AND SUNLINK HEALTH SYSTEMS REVISE ALL-STOCK MERGER TRANSACTION

April 15, 2025 | markets.businessinsider.com

SunLink Health Systems, Inc. Announces Fiscal 2025 Second Quarter Results

February 12, 2025 | businesswire.com

Regional Health Properties to merge with Sunlink Health Systems

January 8, 2025 | mcknightsseniorliving.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

QHC, SSY, LVTX, and SNTI Company Descriptions

LAVA Therapeutics NASDAQ:LVTX

$1.52 -0.02 (-1.30%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.52 +0.00 (+0.33%)

As of 08/15/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Quorum Health NYSE:QHC

Quorum Health Corporation, together with its subsidiaries, provides hospital and outpatient healthcare services in the United States. Its hospital and outpatient healthcare services include general and acute care, emergency room, general and specialty surgery, critical care, internal medicine, diagnostic, obstetric, psychiatric, and rehabilitation services. Quorum Health Corporation offers its healthcare services through its hospitals and affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics, and surgery centers. The company, through its subsidiary, Quorum Health Resources, LLC, provides hospital management advisory, healthcare consulting, and group purchasing services to non-affiliated hospitals, as well as Web-based applications and software tools; and various education programs for healthcare leaders, professionals, and other medical staff. As of December 31, 2018, it owned or leased 27 hospitals with approximately 2,604 licensed beds. The company was incorporated in 2015 and is headquartered in Brentwood, Tennessee.

Senti Biosciences NASDAQ:SNTI

$1.52 -0.01 (-0.65%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.04 (+2.89%)

As of 08/15/2025 07:58 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SunLink Health Systems NYSE:SSY

$1.12 +0.16 (+16.56%)

Closing price 08/14/2025 08:00 PM Eastern

Extended Trading

$1.12 0.00 (0.00%)

As of 08/14/2025 08:00 PM Eastern

SunLink Health Systems, Inc., through its subsidiaries, provides healthcare products and services in the southeastern United States. It operates in two segments, Healthcare Services and Pharmacy. The Healthcare Services segment owns and operates a 49-licensed-bed acute care hospital, which includes a 26-bed geriatric psychiatry unit; two clinics; and a 66-bed extended care and rehabilitation centre. This segment also provides information technology services; and owns five acers unimproved lands. The Pharmacy segment offers institutional pharmacy services consisting of provision of specialty and non-specialty pharmaceutical and biological products, such as nursing homes, assisted living facilities, behavioural and specialty hospitals, hospices, and correctional facilities; non-institutional pharmacy services, including private residences; and durable medical equipment products and services, including the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care, as well as retails pharmacy products and services. SunLink Health Systems, Inc. was incorporated in 1959 and is based in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time